Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: biotechnology
Canadian Ruling Supports “Antibody Exception”
In my recent post on the Centocor v. Abbott decision, I noted that the Fed. Cir. had at least preserved the “antibody exception,” which I define as permitting broad claims to structurally uncharacterized antibodies (monoclonal and polyclonal) if the structure … Continue reading
Happy Birthday Patents4Life – We Are 2!
Now some of them are not yet carved in judicial stone, being at various stages of appeal, but the sum of KSR, Bilski (well, I guess it was more pro-patent than the strict M or T test it replaced with … Continue reading
Posted in About SLW
Tagged Ariad, Ariad v. Lilly, Bilski, biotechnology, biotechnology law, biotechnology news, Federal Circuit, intellectual property, ip, IP law tools, KSR, Kubin, Lilly, Myriad, Patent Law, patents, Pharmaceutical law, Prometheus v. Mayo, stem cells, Supreme Court, Warren Woessner
1 Comment
Divided We Fall – New Rules Limit Divisional Applications in Australia
This is a guest post from Bill Bennett of Pizzeys. Where a divisional application presents claims for examination which have been previously rejected in the parent (or grand-parent) application, then the APO will give the applicant only 2 months to … Continue reading